Home About Titan Pharmaceuticals Products Press Releases Financials Resources: Scientific Articles and Presentations Contact Us

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Titan Pharmaceuticals, Inc. presented at the 7th annual LD Micro "Main Event" Micro-Cap Growth Conference on Dec. 4. The presentation reviewed progress of the Phase 3 development program for Probuphine® for the maintenance treatment of opioid dependence and of the potential re-submission of the Probuphine New Drug Application (NDA), and provided an overview of the company’s ProNeura for Parkinson's disease program and key company milestones for 2015. Click here for an archived webcast of the presentation.

Titan Pharmaceuticals Fourth Quarter and Full Year 2014 Financial Results

Wednesday, April 1, 2015 - 10:00AM PT | 1:00PM ET

Participant Toll Free: 888-576-4398 | Participant Passcode: 2661186
THE EVENT/REGISTRATION PAGE URL FOR THE WEBCAST IS: http://www.visualwebcaster.com/event.asp?id=101962

 

Titan Pharmaceuticals Latest Press Releases

South San Francisco, CA – March 31, 2015Titan Pharmaceuticals, Inc. (TTNP.OB), today reported financial results for the fourth quarter and year ended December 31, 2014. Total revenues for the year 2014 were approximately $3.6 million compared with approximately $10.5 million in 2013. Revenue in 2014 was all related to the amortization of the upfront license fee received from commercialization partner Braeburn Pharmaceuticals in December 2012. Revenues in 2013 consisted of approximately $9.1 million related to the amortization of the upfront license fee and approximately $1.4 million in royalty revenues on net sales of Fanapt®, which were paid by Titan to Deerfield Management.

Read Press Release » »

South San Francisco, CA – March 25, 2015Titan Pharmaceuticals, Inc. (TTNP.OB), today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Wednesday, April 1, 2014 to discuss the company’s financial results as of December 31, 2014. The call will be hosted by Sunil Bhonsle, president; Kate Glassman Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the fourth quarter and full year financial results will be included in a press release to be issued prior to the call.

Read Press Release » »

South San Francisco, CA – March 3, 2015 – Titan Pharmaceuticals, Inc. (TTNP.OB), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term drug delivery technology, announced today that Titan President Sunil Bhonsle will present at the 27th annual ROTH Conference on Monday, March 9 at 9:30 a.m. PT at The Ritz-Carlton in Laguna Niguel, Calif.

Read Press Release » »

South San Francisco, CA – Jan. 6, 2015Titan Pharmaceuticals, Inc. (TTNP.OB), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term drug delivery technology, announced today that its President, Sunil Bhonsle, will present at the 8th annual OneMedForum taking place on January 12-13, 2015 in San Francisco. The presentation is scheduled for Jan. 12 at 11 a.m. in the Public Company Track Room, Marriott Marquis, San Francisco, California.

Read Press Release » »

Read more Titan Pharmaceuticals Press Releases

Probuphine®

Probuphine is Titan’s novel subdermal implant formulation designed using its ProNeura technology to deliver six months of buprenorphine hydrochloride (“buprenorphine”) following a single treatment. Probuphine is being developed for the treatment of opioid dependence...

 

Read More... »»

 

Probuphine® Program Update

 

April. 15, 2015
Phase 3 Study Completion on Schedule for Late Q2, 2015

Titan announced completion of patient enrollment in the Phase 3 study of Probuphine®, the company’s investigational subdermal implant for the maintenance treatment of opioid dependence, on Nov. 30. The study is expected to be completed on schedule by the end of the second quarter ...

 

Read More... »»

 

Titan Pharmaceuticals, Inc. is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of central nervous system (“CNS”) disorders.

Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. The outpatient treatment of opioid dependence with daily dosed sublingual buprenorphine formulations represents a $1.5 billion market in the U.S., and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011.  This novel implant formulation is inserted subdermally in a patient’s upper arm providing continuous medication...

 

Read more... » »